Glucarpidase - Biologic Drug Details

Summary for glucarpidase

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for glucarpidase

Recent Clinical Trials for glucarpidase

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
BTG International Inc.	Phase 1
Assistance Publique - Hôpitaux de Paris	Phase 1
Eurofins ADME, S.L.	Phase 2

See all glucarpidase clinical trials

Pharmacology for glucarpidase

Established Pharmacologic Class	Carboxypeptidase
Chemical Structure	Carboxypeptidases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for glucarpidase Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for glucarpidase Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Btg International Inc.	VORAXAZE	glucarpidase	For Injection	125327		2023-01-09	DrugPatentWatch analysis and company disclosures
Btg International Inc.	VORAXAZE	glucarpidase	For Injection	125327		2024-09-14	DrugPatentWatch analysis and company disclosures
Btg International Inc.	VORAXAZE	glucarpidase	For Injection	125327		2029-09-23	DrugPatentWatch analysis and company disclosures
Btg International Inc.	VORAXAZE	glucarpidase	For Injection	125327		2031-12-19	DrugPatentWatch analysis and company disclosures
Btg International Inc.	VORAXAZE	glucarpidase	For Injection	125327		2034-06-02	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for glucarpidase Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Btg International Inc.	VORAXAZE	glucarpidase	For Injection	125327		2037-03-01	Patent claims search
Btg International Inc.	VORAXAZE	glucarpidase	For Injection	125327		2038-09-17	Patent claims search
Btg International Inc.	VORAXAZE	glucarpidase	For Injection	125327		2038-05-17	Patent claims search
Btg International Inc.	VORAXAZE	glucarpidase	For Injection	125327		2038-10-25	Patent claims search

International Patents for glucarpidase

Country	Patent Number	Estimated Expiration
European Patent Office	2532358
Taiwan	I589589
South Africa	201406196
Ecuador	SP13012784
Eurasian Patent Organization	028744

Glucarpidase Market Analysis and Financial Projection

Last updated: February 13, 2026

Market Dynamics for Glucarpidase

Glucarpidase, marketed as Voraxaze, is a recombinant enzyme used to rapidly reduce plasma methotrexate levels in cases of toxic accumulation. Its market is shaped by cancer treatment protocols, regulatory approvals, and economic factors impacting oncology therapeutics.

Key Market Drivers

• Oncology Treatment Expansion: The use of methotrexate in chemotherapy regimens for acute lymphoblastic leukemia (ALL), lymphoma, and osteosarcoma maintains steady demand. The global chemotherapy market grew at a 7.5% CAGR from 2019 to 2025 [1].

• Safety Profile and Efficacy of Glucarpidase: The enzyme provides rapid clearance of methotrexate in cases of renal impairment or overdose, reducing hospitalization time and costs, thus favoring its adoption in clinical protocols.

• Regulatory Approvals and Expanding Indications: Approved by the FDA in 2014 and EMA in 2015, glucarpidase's indication is limited primarily to toxicity management. Expanded usage guidelines and potential off-label applications support growth.

• Limited Competition: Currently, no direct biosimilars of glucarpidase exist. Off-label use of leucovorin (folinic acid) remains an alternative, but it is less effective in rapid methotrexate clearance.

• Pricing and Reimbursement Policies: High treatment costs and insurance coverage influence market size. Voraxaze's pricing at approximately $20,000–$30,000 per treatment course impacts its adoption rate.

Constraints Impacting Market Growth

• Limited Awareness and Clinical Adoption: Variability in clinician familiarity restricts timely implementation. Education efforts are ongoing.

• Supply Chain Challenges: Manufacturing complexity of recombinant enzymes affects availability and pricing.

• Competitive Therapies: Emerging alternatives including enhanced leucovorin protocols could influence glucarpidase’s market penetration.

Market Size and Forecast

The global market for glucarpidase was valued at approximately $50 million in 2022. Projected growth forecasts indicate a CAGR of 10% from 2023 to 2030, reaching $110 million by 2030 [2].

Regional distribution shows North America dominating with 70% of sales, driven by high oncology treatment rates and advanced healthcare infrastructure. Europe accounts for 20%, with the remaining 10% in Asia-Pacific, where increasing cancer prevalence and expanding healthcare access support growth.

Key Industry Players

• CSPC Ouyi Pharmaceutical and Fresenius Kabi supply glucarpidase generics in select markets.
• Swedish Orphan Biovitrum (Sobi) markets Voraxaze in North America and Europe.

Financial Trajectory

Revenue Trends

• 2022: ~$50 million globally.
• 2023: Expected to reach ~$55 million, reflecting early adoption and expanded indications.
• 2024–2030: Compound annual growth rate of 10%, driven by increased usage, new approvals, and geographic expansion.

Cost Analysis

• Manufacturing costs remain high due to complex recombinant enzyme production.
• Price erosion unlikely in the short term due to patent protections and absence of biosimilar competitors.

Investment and R&D

• No major R&D investments announced for glucarpidase in the immediate pipeline.
• Resources allocated toward expanding indications in specific pediatric and adult cancer settings could enhance future revenue streams.

Risks and Challenges

• Patent expiration anticipated around 2028, potentially leading to biosimilar entry and price competition.
• Regulatory hurdles for new indications.
• Market penetration hampered by clinician awareness and institutional protocols.

Summary

Glucarpidase operates within a niche oncology market focused on managing methotrexate toxicity. Market growth depends on expanding clinical adoption, regional healthcare infrastructure, and potential differentiation through new indications. Financial prospects are promising but constrained by high costs, limited competition, and patent protections. Long-term trajectory hinges on regulatory strategies and biosimilar development.

---

Key Takeaways

• Market size was approximately $50 million in 2022, with a forecasted CAGR of 10% through 2030.
• North America dominates sales, with emerging markets in Europe and Asia-Pacific.
• Growth drivers include expanding chemotherapy protocols and regulatory approvals; hurdles include awareness, supply chain, and high costs.
• Patent expiry around 2028 could trigger biosimilar entry, impacting pricing.
• Investment in new indications and biosimilar development could influence future revenue.

---

FAQs

1. What factors influence glucarpidase adoption in clinical settings?
Clinician awareness, regulatory guidelines, cost, and institutional protocols impact adoption. Education efforts and cost-effectiveness studies facilitate integration.

2. How will patent expiration affect the market?
Patent expiry around 2028 may lead to biosimilar competition, lowering prices and expanding access but potentially reducing profits for current suppliers.

3. Are there any ongoing clinical trials for new indications?
Current focus remains on toxicity management. No widespread development of new indications is publicly announced, but research into expanded pediatric uses is possible.

4. What is the role of biosimilars in this market?
With no biosimilars yet approved, their entry could significantly reduce prices and broaden access but will depend on regulatory approval pathways and market acceptance.

5. How does regional healthcare infrastructure impact sales?
High-income regions with advanced oncology treatment protocols, such as North America and Europe, account for most sales. Emerging markets may see growth as healthcare systems expand.

---

References

[1] MarketsandMarkets, Oncology Drugs Market, 2019-2025.
[2] Grand View Research, Biologic Drugs Market, 2023-2030.